- Investing Ideas
- Swiss Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Swiss Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
5
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
5 companies
Galderma Group
Market Cap: CHF 38.1b
Operates as a dermatology company worldwide.
GALD
CHF 162.35
7D
-0.2%
1Y
44.3%
Sandoz Group
Market Cap: CHF 27.2b
Develops, manufactures, and markets generic and biosimilars worldwide.
SDZ
CHF 62.90
7D
-2.5%
1Y
48.2%
Bachem Holding
Market Cap: CHF 5.1b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 67.90
7D
-15.7%
1Y
34.6%
Tecan Group
Market Cap: CHF 2.0b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 156.90
7D
4.2%
1Y
-2.3%
Basilea Pharmaceutica
Market Cap: CHF 617.9m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 49.85
7D
-6.8%
1Y
7.6%